DE69231263D1 - Calcitonin enthaltende pharmazeutische Zusammensetzungen - Google Patents

Calcitonin enthaltende pharmazeutische Zusammensetzungen

Info

Publication number
DE69231263D1
DE69231263D1 DE69231263T DE69231263T DE69231263D1 DE 69231263 D1 DE69231263 D1 DE 69231263D1 DE 69231263 T DE69231263 T DE 69231263T DE 69231263 T DE69231263 T DE 69231263T DE 69231263 D1 DE69231263 D1 DE 69231263D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions containing
containing calcitonin
calcitonin
calcium deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69231263T
Other languages
English (en)
Other versions
DE69231263T2 (de
Inventor
Tudor Arvinte
Amelia Cudd
Judith Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69231263D1 publication Critical patent/DE69231263D1/de
Publication of DE69231263T2 publication Critical patent/DE69231263T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE69231263T 1991-04-23 1992-04-21 Calcitonin enthaltende pharmazeutische Zusammensetzungen Expired - Fee Related DE69231263T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108634A GB9108634D0 (en) 1991-04-23 1991-04-23 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69231263D1 true DE69231263D1 (de) 2000-08-24
DE69231263T2 DE69231263T2 (de) 2000-12-21

Family

ID=10693744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231263T Expired - Fee Related DE69231263T2 (de) 1991-04-23 1992-04-21 Calcitonin enthaltende pharmazeutische Zusammensetzungen

Country Status (19)

Country Link
US (1) US5593962A (de)
EP (1) EP0510913B1 (de)
JP (1) JP3532580B2 (de)
KR (1) KR100245534B1 (de)
AT (1) ATE194775T1 (de)
AU (1) AU653395B2 (de)
CA (1) CA2066532C (de)
CY (1) CY2246B1 (de)
DE (1) DE69231263T2 (de)
DK (1) DK0510913T3 (de)
ES (1) ES2150418T3 (de)
GB (1) GB9108634D0 (de)
GR (1) GR3034414T3 (de)
IE (1) IE921278A1 (de)
IL (1) IL101622A (de)
MX (1) MX9201825A (de)
NZ (1) NZ242440A (de)
PT (1) PT510913E (de)
ZA (1) ZA922899B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
EP1161257A2 (de) 1999-03-17 2001-12-12 Novartis AG Tgf-beta enthaltende pharmazeutische zusammensetzungen
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
US7884071B2 (en) 2002-09-27 2011-02-08 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CN102088997A (zh) 2008-04-07 2011-06-08 国家免疫研究所 用于治疗糖尿病和其他慢性疾病的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions

Also Published As

Publication number Publication date
GB9108634D0 (en) 1991-06-12
JPH05139993A (ja) 1993-06-08
CA2066532C (en) 2003-08-19
PT510913E (pt) 2000-12-29
ATE194775T1 (de) 2000-08-15
GR3034414T3 (en) 2000-12-29
IL101622A (en) 1996-06-18
EP0510913A3 (en) 1993-12-15
EP0510913B1 (de) 2000-07-19
DE69231263T2 (de) 2000-12-21
AU653395B2 (en) 1994-09-29
AU1506692A (en) 1992-10-29
CY2246B1 (en) 2003-07-04
IL101622A0 (en) 1992-12-30
MX9201825A (es) 1992-10-01
NZ242440A (en) 1993-10-26
US5593962A (en) 1997-01-14
CA2066532A1 (en) 1992-10-24
ZA922899B (en) 1993-10-22
JP3532580B2 (ja) 2004-05-31
EP0510913A2 (de) 1992-10-28
ES2150418T3 (es) 2000-12-01
KR100245534B1 (ko) 2000-03-02
IE921278A1 (en) 1992-11-04
DK0510913T3 (da) 2000-10-16

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
MX9204229A (es) Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.
DE68909691D1 (de) Multischichtkörper zur Abgabe von Duftstoffen.
ATA129892A (de) Pharmazeutische zusammensetzung
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
LV12284A (lv) No kudras izdaliti bioaktivi produkti un tos saturosas farmaceitiskas un kosmetiskas kompozicijas
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
IL87421A0 (en) Pharmaceutical compositions containing 5-amino(or substituted amino)-1,2,3-triazoles
SE9802937D0 (sv) Novel compounds
DE3864210D1 (de) Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
ATE194775T1 (de) Calcitonin enthaltende pharmazeutische zusammensetzungen
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE69434210D1 (de) Pharmazeutische antacidzusammensetzung
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
MX9202507A (es) Composicion farmaceutica para el tratamiento de esofagitis de reflujo.
ATE231728T1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
DE59705525D1 (de) Kombinationspräparat enthaltend Tramadol und einen Calcium-Kanal Antagonisten
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
DE69003003D1 (de) Pharmazeutische Zusammensetzung.
DE68905343D1 (de) Dosisform zur verabreichung von calciumantagonisten.
ATE86481T1 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee